Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China Pharma Reports Higher Q3; Accounts Receivable also Up

publication date: Nov 10, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Pharma Holdings reported its Q3 revenues climbed 52% to $12.61 million and net income was up 38% to $4.25 million, which equates to 10 cents per share fully diluted. Unfortunately, China Pharma is having trouble with cash flow. Its Accounts Receivables have ballooned during the first nine months of the year, rising from $19 million to $32 million, a fact that has largely offset the beneficial effects of China Pharma’s profits. More details...

Stock Symbol: (NSDQ: CPHI)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners